Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serrate RNA effector molecule homolog (SRRT, also known as ARS2) is a nuclear RNA-binding protein encoded by the human SRRT gene. It acts as a mediator between the mRNA cap-binding complex and primary microRNA processing machinery, supporting the delivery and stability of capped precursor miRNAs for RNAi gene silencing. SRRT/ARS2 also assists cell cycle progression around S phase and is crucial for neural stem cell maintenance by activating SOX2 transcription. The protein can modulate cellular sensitivity to arsenic but does not directly confer arsenic resistance in humans. Diseases linked with SRRT dysfunction include cerebral arteriopathy with subcortical infarcts and leukoencephalopathy and spondylocostal dysostosis. It functions mainly as a scaffold, binding capped RNAs and recruiting elements of the RNA processing and decay machinery. No drugs are currently available that target SRRT directly.
Not applicable; no known drugs specifically modulate this protein directly. The molecule acts as a platform and scaffold for RNA-processing machinery and cap-binding complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serrate RNA effector molecule homolog (SRRT).